Publications by authors named "H T Ma"

The coordination of public and private goods production is essential for bacterial adaptation to environmental changes. Quorum sensing (QS) regulates this balance by mediating the trade-off between the communal benefits of "public goods," such as siderophores and antibiotics, and the individual metabolic needs fulfilled by "private goods," such as intracellular metabolites utilized for growth and survival. Pseudomonas fluorescens 2P24 harbors a LasI/LasR-type QS system, MupI/MupR, which regulates mupirocin production through signaling molecules.

View Article and Find Full Text PDF

Circularly polarized luminescence (CPL) materials are attractive due to their unique applications in fields such as 3D displays, information encryption, and chiroptical switches. Natural biomolecules-based CPL materials are gaining plenty of attention due to their chiral diversity and sustainability. However, it is still challenging to construct CPL materials with opposite CPL signs from a single natural biomolecule due to its inherent chirality.

View Article and Find Full Text PDF

Despite advances in multimodal cancer therapy, such as combining radical surgery with high-intensity chemoradiotherapy, for SMARCB1/INI-1-deficient sinonasal carcinoma (SDSC), the prognosis of patients remains poor. Immunotherapy is gaining increasing popularity as a novel treatment strategy for patients with SMARCB1/INI-1-deficient tumors. Herein, we report on the management of three patients with SDSC who received PD-1/PD-L1 inhibitor therapy as a part of multimodal therapy based on surgery and chemoradiotherapy.

View Article and Find Full Text PDF

Objective: Fast progression (FP) represents a desperate situation for advanced non-small cell lung cancer (NSCLC) patients undergoing immune checkpoint inhibitor therapy. We aimed to develop a predictive framework based on machine learning (ML) methods to identify FP in advanced NSCLC patients using blood test biomarkers.

Methods And Analysis: We extracted data of 1546 atezolizumab-treated patients from four multicentre clinical trials.

View Article and Find Full Text PDF